Prospective assessment of circulating tumor cells (CTCs) in women undergoing surgery for suspected ovarian cancer

Lou, Emil; Gerber, Matthew S.; Grad, A.; Monu, Minnu; Lukaszewski, T; Hoostal, Spencer; Deshpande, Jaai; Teoh, Deanna; Linden, Malaïka Van Der; Geller, Melissa A.

doi:10.1016/j.ygyno.2017.03.215

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Primary debulking surgery has become the favored first step in the management of advanced ovarian cancer [7]. Our purpose aims to evaluate the upfront role of neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) in advanced ovarian cancer (III/IV) versus primary debulking surgery followed by chemotherapy (PDS-ACTR).…”

Section: A H Zaky Et Almentioning

confidence: 99%

“…Although advances in diagnosis and management of epithelial ovarian cancer have changed in the last 25 years, the overall survival has not been improved as approximately 65% to 70% of all ovarian cancer continues to be diagnosed with advanced stage (III or IV). Primary optimal debulking surgery has become the standard step in the management of advanced epithelial ovarian cancer [7]. When optimal debulking cannot be achieved, little benefit from debulking surgery will be gained [8].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Feasibility of Upfront Debulking Surgery versus Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery for Advanced Ovarian Cancer

Zaky¹,

Gabr²,

Maximous³

et al. 2018

JCT

View full text Add to dashboard Cite

Background: Inappropriately ovarian cancer cannot be detected until an advanced stage. Radical debulking surgery is considered the cornerstone in the management of advanced ovarian cancer pointing to complete tumor resolution. Unless optimal debulking cannot be achieved, these patients gain little benefit from surgery. Neoadjuvant chemotherapy (NACT) has been recommended as a novel therapeutic modality to a diversity of malignant tumors when the disease is not willing to optimal surgical resection at the time of diagnosis or the patient who unfit for aggressive debulking surgery. The purpose of this study is to compare survival in the patient with advanced ovarian cancer (stage III/IV) underwent primary debulking surgery followed by adjuvant chemotherapy (PDS-ACTR) to those who received neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS). Results: Neoadjuvant chemotherapy (NACT-IDS) showed significant complete cytoreduction and decreased in surgical morbidity in comparison to primary debulking surgery (PDS-ACTR). NACT-IDS showed significant improvement in progression-free survival (P-value 0.002) and overall survival (P-value 0.03) in comparison to PDS-ACTR. Response to NACT and residual volume were the two independent prognostic factors for overall survival. Conclusion: NACT-IDS for advanced ovarian cancer (III/IV) resulted in higher frequency of complete resection with no residual tumor, less post-operative surgical morbidity and 146 Journal of Cancer Therapy significant increase progression-free survival and overall survival. Both responses to NACT and residual tumor volume were the two independent prognostic factors for survival in ovarian cancer.

show abstract

Section: A H Zaky Et Almentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%